低强度PSA筛查干预对前列腺癌死亡率的影响:CAP随机临床试验
CAP集群随机试验纳入419 582名50至69岁男性,比较单次PSA筛查邀请与标准未筛查实践,中位随访10年。
要点
- 单次PSA筛查未显著降低10年前列腺癌死亡率(RR 0.96,95%CI 0.85-1.08)。
核心结论
- 在50至69岁男性中,单次PSA筛查干预与标准未筛查实践相比,中位随访10年前列腺癌死亡率无显著差异。
- 单次PSA筛查增加了低危前列腺癌的检出,研究结果不支持单次PSA检测用于人群筛查。
研究设计与样本
- CAP为集群随机临床试验,在英国573个初级保健机构开展,随机化与招募于2001至2009年间完成。
- 共纳入419 582名50至69岁男性,纳入分析408 825人(98%),干预组189 386人,对照组219 439人。
- 干预为邀请参加PSA检测诊所并接受单次PSA检测,对照为标准未筛查实践。
- 主要结局为中位随访10年的前列腺癌特异性死亡率。
主要发现
- 干预组75 707人(40%)参加PSA检测诊所,67 313人(36%)接受PSA检测。
- 64 436份有效PSA结果中,6857份(11%)PSA在3至19.9 ng/mL之间,其中5850人(85%)接受了前列腺活检。
关键数值与推荐
- PSA阈值:3至19.9 ng/mL被视为有效检测结果中的异常范围,其中85%接受了活检。
- Gleason分级范围2-10分,分数越高预后越差。
临床怎么用
- 单次PSA筛查不应作为人群基于人群的筛查策略,因其未降低前列腺癌死亡率且增加低危病例检出。
- 临床决策中需权衡PSA筛查的潜在获益与过度诊断、过度治疗的风险。
局限性
- 干预组仅40%参加PSA检测诊所、36%接受PSA检测,依从性可能影响结果解释。
- 中位随访10年,更长期随访仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment. OBJECTIVE: To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer-specific mortality. DESIGN, SETTING, AND PARTICIPANTS: The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) included 419 582 men aged 50 to 69 years and was conducted at 573 primary care practices across the United Kingdom. Randomization and recruitment of the practices occurred between 2001 and 2009; patient follow-up ended on March 31, 2016. INTERVENTION: An invitation to attend a PSA testing clinic and receive a single PSA test vs standard (unscreened) practice. MAIN OUTCOMES AND MEASURES: Primary outcome: prostate cancer-specific mortality at a median follow-up of 10 years. Prespecified secondary outcomes: diagnostic cancer stage and Gleason grade (range, 2-10; higher scores indicate a poorer prognosis) of prostate cancers identified, all-cause mortality, and an instrumental variable analysis estimating the causal effect of attending the PSA screening clinic. RESULTS: Among 415 357 randomized men (mean [SD] age, 59.0 [5.6] years), 189 386 in the intervention group and 219 439 in the control group were included in the analysis (n = 408 825; 98%). In the intervention group, 75 707 (40%) attended the PSA testing clinic and 67 313 (36%) underwent PSA testing. Of 64 436 with a valid PSA test result, 6857 (11%) had a PSA level between 3 ng/mL and 19.9 ng/mL, of whom 5850 (85%) had a prostate biopsy. After a median follow-up of 10 years, 549 (0.30 per 1000 person-years) died of prostate cancer in the intervention group vs 647 (0.31 per 1000 person-years) in the control group (rate difference, -0.013 per 1000 person-years [95% CI, -0.047 to 0.022]; rate ratio [RR], 0.96 [95% CI, 0.85 to 1.08]; P = .50). The number diagnosed with prostate cancer was higher in the intervention group (n = 8054; 4.3%) than in the control group (n = 7853; 3.6%) (RR, 1.19 [95% CI, 1.14 to 1.25]; P < .001). More prostate cancer tumors with a Gleason grade of 6 or lower were identified in the intervention group (n = 3263/189 386 [1.7%]) than in the control group (n = 2440/219 439 [1.1%]) (difference per 1000 men, 6.11 [95% CI, 5.38 to 6.84]; P < .001). In the analysis of all-cause mortality, there were 25 459 deaths in the intervention group vs 28 306 deaths in the control group (RR, 0.99 [95% CI, 0.94 to 1.03]; P = .49). In the instrumental variable analysis for prostate cancer mortality, the adherence-adjusted causal RR was 0.93 (95% CI, 0.67 to 1.29; P = .66). CONCLUSIONS AND RELEVANCE: Among practices randomized to a single PSA screening intervention vs standard practice without screening, there was no significant difference in prostate cancer mortality after a median follow-up of 10 years but the detection of low-risk prostate cancer cases increased. Although longer-term follow-up is under way, the findings do not support single PSA testing for population-based screening. TRIAL REGISTRATION: ISRCTN Identifier: ISRCTN92187251.
引用
- Martin RM, Donovan JL, Turner EL, et al. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. JAMA. 2018. PMID: 29509864. doi:10.1001/jama.2018.0154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。